The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study
Identifieur interne : 004E85 ( Main/Curation ); précédent : 004E84; suivant : 004E86The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study
Auteurs : van Laar ; Bob Van Hilten ; Cees Neef ; A. Wijnand F. Rutgers ; Stan Pavel ; J. Anthony BruijnSource :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
- Abdominal Muscles (pathology), Allergic reactions, Antiparkinson Agents (adverse effects), Apomorphine, Apomorphine (adverse effects), Chelating Agents (adverse effects), Drug Combinations, Drug Eruptions (pathology), EDTA, Edetic Acid (adverse effects), Female, Humans, Injections, Subcutaneous, Intervention Studies, Longitudinal Studies, Male, Middle Aged, Subcutaneous nodules, Vasculitis, Leukocytoclastic, Cutaneous (chemically induced), Vasculitis, Leukocytoclastic, Cutaneous (pathology).
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Apomorphine, Chelating Agents, Edetic Acid.
- chemically induced : Vasculitis, Leukocytoclastic, Cutaneous.
- pathology : Abdominal Muscles, Drug Eruptions, Vasculitis, Leukocytoclastic, Cutaneous.
- chemical : Drug Combinations, Female, Humans, Injections, Subcutaneous, Intervention Studies, Longitudinal Studies, Male, Middle Aged.
Abstract
One of the formulations of apomorphine, used in clinical practice, contains sodium edetate (EDTA). EDTA is a chelator which indirectly prevents oxidation of apomorphine. A clinical and histologic study in four patients revealed that apomorphine with EDTA caused severe subcutaneous nodules, histologically characterized by an inflammatory infiltrate with a large amount of eosinophils, indicating a cell‐mediated allergic reaction. After withdrawal of EDTA, this allergic component completely disappeared, which was accompanied clinically by less extensive nodule formation with a softer consistency. It is therefore recommended that EDTA be excluded from apomorphine formulations.
Url:
DOI: 10.1002/mds.870130113
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003556
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :003556
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003620
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004517
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :004517
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004318
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004E68
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :004E68
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :004E68
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :007D97
Links to Exploration step
ISTEX:02347E989E81A2D17EF3F66851FD28752E163E26Curation
No country items
van Laar<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
<affiliation><wicri:noCountry code="subField">Hospital Medisch Spectrum Twente</wicri:noCountry>
</affiliation>
<affiliation><wicri:noCountry code="subField">Martini Hospital Groningen</wicri:noCountry>
</affiliation>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study</title>
<author><name sortKey="Van Laar" sort="Van Laar" uniqKey="Van Laar" last="Van Laar">van Laar</name>
</author>
<author><name sortKey="Van Hilten, Bob" sort="Van Hilten, Bob" uniqKey="Van Hilten B" first="Bob" last="Van Hilten">Bob Van Hilten</name>
</author>
<author><name sortKey="Neef, Cees" sort="Neef, Cees" uniqKey="Neef C" first="Cees" last="Neef">Cees Neef</name>
</author>
<author><name sortKey="Rutgers, A Wijnand F" sort="Rutgers, A Wijnand F" uniqKey="Rutgers A" first="A. Wijnand F." last="Rutgers">A. Wijnand F. Rutgers</name>
</author>
<author><name sortKey="Pavel, Stan" sort="Pavel, Stan" uniqKey="Pavel S" first="Stan" last="Pavel">Stan Pavel</name>
</author>
<author><name sortKey="Anthony Bruijn, J" sort="Anthony Bruijn, J" uniqKey="Anthony Bruijn J" first="J." last="Anthony Bruijn">J. Anthony Bruijn</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:02347E989E81A2D17EF3F66851FD28752E163E26</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130113</idno>
<idno type="url">https://api.istex.fr/document/02347E989E81A2D17EF3F66851FD28752E163E26/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003556</idno>
<idno type="wicri:Area/Istex/Curation">003556</idno>
<idno type="wicri:Area/Istex/Checkpoint">003620</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Van Laar:the:role:of</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9452326</idno>
<idno type="wicri:Area/PubMed/Corpus">004517</idno>
<idno type="wicri:Area/PubMed/Curation">004517</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004318</idno>
<idno type="wicri:Area/Ncbi/Merge">004E68</idno>
<idno type="wicri:Area/Ncbi/Curation">004E68</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004E68</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Van Laar T:the:role:of</idno>
<idno type="wicri:Area/Main/Merge">007D97</idno>
<idno type="wicri:Area/Main/Curation">004E85</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study</title>
<author><name sortKey="Van Laar" sort="Van Laar" uniqKey="Van Laar" last="Van Laar">van Laar</name>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Van Hilten, Bob" sort="Van Hilten, Bob" uniqKey="Van Hilten B" first="Bob" last="Van Hilten">Bob Van Hilten</name>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Neef, Cees" sort="Neef, Cees" uniqKey="Neef C" first="Cees" last="Neef">Cees Neef</name>
<affiliation><wicri:noCountry code="subField">Hospital Medisch Spectrum Twente</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Rutgers, A Wijnand F" sort="Rutgers, A Wijnand F" uniqKey="Rutgers A" first="A. Wijnand F." last="Rutgers">A. Wijnand F. Rutgers</name>
<affiliation><wicri:noCountry code="subField">Martini Hospital Groningen</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Pavel, Stan" sort="Pavel, Stan" uniqKey="Pavel S" first="Stan" last="Pavel">Stan Pavel</name>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Anthony Bruijn, J" sort="Anthony Bruijn, J" uniqKey="Anthony Bruijn J" first="J." last="Anthony Bruijn">J. Anthony Bruijn</name>
<affiliation><wicri:noCountry code="subField">University Hospital Leiden</wicri:noCountry>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-01">1998-01</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="52">52</biblScope>
<biblScope unit="page" to="55">55</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">02347E989E81A2D17EF3F66851FD28752E163E26</idno>
<idno type="DOI">10.1002/mds.870130113</idno>
<idno type="ArticleID">MDS870130113</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abdominal Muscles (pathology)</term>
<term>Allergic reactions</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Apomorphine</term>
<term>Apomorphine (adverse effects)</term>
<term>Chelating Agents (adverse effects)</term>
<term>Drug Combinations</term>
<term>Drug Eruptions (pathology)</term>
<term>EDTA</term>
<term>Edetic Acid (adverse effects)</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Subcutaneous</term>
<term>Intervention Studies</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Subcutaneous nodules</term>
<term>Vasculitis, Leukocytoclastic, Cutaneous (chemically induced)</term>
<term>Vasculitis, Leukocytoclastic, Cutaneous (pathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Apomorphine</term>
<term>Chelating Agents</term>
<term>Edetic Acid</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Vasculitis, Leukocytoclastic, Cutaneous</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Abdominal Muscles</term>
<term>Drug Eruptions</term>
<term>Vasculitis, Leukocytoclastic, Cutaneous</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Drug Combinations</term>
<term>Female</term>
<term>Humans</term>
<term>Injections, Subcutaneous</term>
<term>Intervention Studies</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">One of the formulations of apomorphine, used in clinical practice, contains sodium edetate (EDTA). EDTA is a chelator which indirectly prevents oxidation of apomorphine. A clinical and histologic study in four patients revealed that apomorphine with EDTA caused severe subcutaneous nodules, histologically characterized by an inflammatory infiltrate with a large amount of eosinophils, indicating a cell‐mediated allergic reaction. After withdrawal of EDTA, this allergic component completely disappeared, which was accompanied clinically by less extensive nodule formation with a softer consistency. It is therefore recommended that EDTA be excluded from apomorphine formulations.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004E85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004E85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:02347E989E81A2D17EF3F66851FD28752E163E26 |texte= The role of EDTA in provoking allergic reactions to subcutaneous infusion of apomorphine in patients with Parkinson's disease: A histologic study }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |